Abstract
Article: Focal Nodular Hyperplasia: Case Study, Imaging, and Treatment
Authors: Chelsey N. McCann, RT(R), RDMS, and Steven M. Penny, BS, RT(R), RDMS
Category: Abdomen
Credit: 1.0 SDMS CME Credit
Objectives: After studying the article entitled “Focal Nodular Hyperplasia: Case Study, Imaging, and Treatment,” you will be able to:
Explain the risk factors for development of focal nodular hyperplasia
Describe the sonographic imaging findings associated with focal nodular hyperplasia
Determine the role of ultrasound contrast in the evaluation of liver lesions
Focal nodular hyperplasia (FNH) is the _______ most common benign hepatic mass.
First Second Third Fourth
FNH is coexistent with hepatic hemangioma in approximately what percentage of patients?
10%–15% 15%–20% 20%–25% 25%–30%
FNH is coexistent with hepatocellular carcinoma in approximately what percentage of patients?
2% 3% 4% 5%
The typical size of an FNH at the time of discovery is approximately
3 mm 6 mm 8 mm 10 mm
Recent studies suggest that FNH is a mass consisting of
Monoclonal cells and is neoplastic in origin Monoclonal cells and is nonneoplastic in origin Polyclonal cells and is neoplastic in origin Polyclonal cells and is nonneoplastic in origin
FNH typically presents clinically with
No symptoms Abdominal pain Right flank pain Intraperitoneal bleeding
A sonographic feature of FNH is a central scar with prominent vasculature, which may appear on imaging to be
Hypoechoic or hyperechoic Always hypoechoic Always hyperechoic Isoechoic
With contrast-enhanced ultrasound, FNH shows hypervascularity during the
Injection phase Arterial phase Venous phase Washout phase
Contrast-enhanced ultrasound detects FNH with an accuracy of approximately
60%–65% 70%–75% 85%–90% >95%
Current recommended management of asymptomatic FNH is
Surgical resection Cryoablation Embolization of the central vessel Routine sonographic surveillance
Footnotes